The Role of Fcγ Receptor Polymorphisms in the Response to Anti–Tumor Necrosis Factor Therapy in Psoriasis

Julià, Marc; Guilabert, Antonio; Lozano, Francisco; Suárez-Casasús, Belén; Moreno, Nemesio; Carrascosa, J.M.; Ferrándiz, Carlos; Pedrosa, E.; Alsina-Gibert, Mercè; Mascaró, José M.

doi:10.1001/jamadermatol.2013.4632

Cited by 39 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, pharmacogenetic studies of FCGR2A and FCGR3A gene variants and anti-TNF therapy response have provided suggestive evidence for opposite genetic effects between rheumatoid arthritis and Crohn's disease, 33 rheumatoid arthritis and psoriatic arthritis 34 and even between rheumatoid arthritis and psoriasis. 20 Taken together, these results support the existence of different TNFrelated pathways and, consequently, different biologic mechanisms by which TNF blocking is an effective treatment.…”

Section: Discussionmentioning

confidence: 63%

“…The PASI response measures the percentage of improvement in disease activity relative to a specified baseline. 20 The use of a relative score has the added advantage that it avoids any potential bias associated with different levels of disease activity at baseline. The association of the rs3794271 SNP genetic variation with the PASI response was performed using linear regression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

Juliá¹,

Ferrándiz

Daudén

et al. 2014

Pharmacogenomics J

View full text Add to dashboard Cite

Psoriasis is a prevalent autoimmune disease of the skin that causes significant psychological and physical disability. Tumor necrosis factor (TNF)-blocking agents have proven to be highly efficacious in the management of moderate-to-severe psoriasis. However, a significant percentage of patients do not respond to this treatment. Recently, variation at the PDE3A-SLCO1C1 (phosphodiesterase 3A-SoLute Carrier Organic anion transporter family member 1C1) locus has been robustly associated with anti-TNF response in rheumatoid arthritis. Using a cohort of 130 psoriasis patients treated with anti-TNF therapy, we sought to analyze the association of this locus with treatment response in psoriasis. We found a highly significant association between PDE3A-SLCO1C1 and the clinical response to TNF blockers (P=0.0031). Importantly, the allele that was previously associated with the lack of response to rheumatoid arthritis (G allele, single-nucleotide polymorphism rs3794271) was associated with a higher anti-TNF efficacy in psoriasis. The results of this study are an important step in the characterization of the pharmacogenetic profile associated with anti-TNF response in psoriasis.

show abstract

Section: Discussionmentioning

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

Juliá¹,

Ferrándiz

Daudén

et al. 2014

Pharmacogenomics J

View full text Add to dashboard Cite

show abstract

“…[33][34][35][36][37][38][39][40][41][42][43] For all significant associations, except TLR9 (rs352139) and LY96 (rs11465996), similar tendencies were observed for ORs for each of the anti-TNF agents (data available on request). To our knowledge, this is one of the largest cohorts for evaluation of response in patients treated with ustekinumab 44,45 and the second largest for evaluation of anti-TNF; only a Canadian study (also involving treatment primarily for psoriatic arthritis) had more patients.…”

Section: Study Populationmentioning

confidence: 61%

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

et al. 2017

View full text Add to dashboard Cite

“…Patients homozygous for high-ainity alleles of two variants FCGR2A-H131R (rs1801274) and FCGR3A-V158F (rs396991) had a higher chance of achieving PASI75 after 3 months of therapy [57]. FCGR3A rs396991 was also evaluated by Mendrinou et al who showed that T allele could be a marker of beter response to etanercept [58].…”

Section: Pharmacogenetics Of Anti-tnfα Treatmentmentioning

confidence: 99%

Pharmacogenetics of Psoriasis Treatment

Redenšek¹,

Dolžan²

2017

An Interdisciplinary Approach to Psoriasis

View full text Add to dashboard Cite

Psoriasis is a chronic systemic, immune-mediated disorder of unknown aetiology, usually presenting with typical inlammatory skin lesions and/or joint manifestations, but systemic inlammation that may lead to the development of co-morbidities may also be present. First-line therapy encompasses local cutaneous treatment and phototherapy, but with more severe symptoms or systemic course, systemic treatment with methotrexate (MTX), immunosuppressant cyclosporine, retinoid acitretin or biologicals may be used. Treatment response varies between patients in terms of eicacy and/or toxicity, which could, among other reasons, be due to genetic diferences between patients. Approximately 10-30% of patients experience adverse drug reactions with MTX treatment, leading to discontinuation of MTX mostly due to hepatotoxicity. Around 15% of patients experience adverse events when treated with biologicals; however, the most frequent reason for discontinuation is ineicacy or loss of the initially favourable response over time. Ineicacy or occurrence of adverse drug reactions cannot be predicted, so genetic biomarkers of drug response in combination with clinical data could be helpful in treatment planning. Several polymorphic genes have already been associated with treatment outcome, most of them involved in drug metabolism, transport and target pathways. Genetic biomarkers could be helpful in personalized care of psoriasis patients in order to prevent adverse events or predict ineicacy of a certain drug.

show abstract

The Role of Fcγ Receptor Polymorphisms in the Response to Anti–Tumor Necrosis Factor Therapy in Psoriasis

Cited by 39 publications

References 32 publications

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

Pharmacogenetics of Psoriasis Treatment

Contact Info

Product

Resources

About